指南与共识其他结缔组织病

2016年ACR/EULAR幼年皮肌炎最小、中度与重大临床缓解标准

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
指南 / 共识 · Arthritis Rheumatol · 2017-04-06

该国际协作项目基于IMACS和PRINTO核心指标集,通过分析312种定义并利用PRINTO试验和RIM试验数据验证,最终共识建立了一个基于联合分析的连续改善评分模型(0-100分),以核心指标集绝对百分比变化定义最小(≥30)、中度(≥45)和重大(≥70)改善。在幼年皮肌炎队列中,最小改善的敏感性和特异性分别为89%和91-98%,中度改善为92-94%和94-99%,重大改善为91-98%和85-86%。

要点

  • 采用0-100分连续改善评分,最小、中度、重大改善阈值分别为≥30、≥45、≥70。
  • 基于IMACS或PRINTO核心指标集的绝对百分比变化计算改善评分。
  • 在幼年皮肌炎队列中验证,敏感性和特异性良好,并能区分治疗组间差异。

核心结论

  • 幼年皮肌炎应答标准为基于联合分析的连续改善评分模型,使用核心指标集绝对百分比变化,设定最小、中度和重大改善阈值。

研究设计与样本

  • 国际肌炎评估和临床研究组(IMACS)与儿科风湿病国际试验组织(PRINTO)协作,分析312种定义的性能,数据来自自然病史和联合分析调查,并在PRINTO试验和RIM试验中验证,最后通过共识会议确定标准。

主要发现

  • 在幼年皮肌炎患者队列中,使用IMACS和PRINTO核心指标集时,最小改善的敏感性和特异性分别为89%和91-98%,中度改善为92-94%和94-99%,重大改善为91-98%和85-86%。
  • 在PRINTO试验中验证了这些标准可区分治疗组间最小和中度改善(P = 0.009-0.057)。
  • 在RIM试验中验证了这些标准可显著区分医生对改善的评级(P < 0.006)。

关键数值与推荐

  • 最小改善阈值:核心指标集绝对百分比变化≥30。
  • 中度改善阈值:核心指标集绝对百分比变化≥45。
  • 重大改善阈值:核心指标集绝对百分比变化≥70。
  • 总改善评分范围为0-100。

临床怎么用

  • 临床中可使用该连续改善评分评估幼年皮肌炎患者对治疗的反应,按阈值分类为最小、中度或重大改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM). METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. RESULTS: Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). CONCLUSION: The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017. PMID: 28382778. doi:10.1002/art.40060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。